Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

32.5%

38 terminated/withdrawn out of 117 trials

Success Rate

60.8%

-25.7% vs industry average

Late-Stage Pipeline

36%

42 trials in Phase 3/4

Results Transparency

86%

51 of 59 completed trials have results

Key Signals

9 recruiting51 with results23 terminated15 withdrawn

Enrollment Performance

Analytics

Phase 2

33(32.4%)

Phase 3

26(25.5%)

Phase 1

21(20.6%)

Phase 4

16(15.7%)

N/A

4(3.9%)

Early Phase 1

2(2.0%)

102Total

Phase 2(33)

Phase 3(26)

Phase 1(21)

Phase 4(16)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (117)

Showing 20 of 117 trials

NCT03626688Phase 3Completed

A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Role: lead

NCT03045029Active Not Recruiting

ADAPT - A Patient Registry of the Real-world Use of Orenitram®

Role: lead

NCT06911632Not ApplicableActive Not Recruiting

Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension

Role: collaborator

NCT05943535Phase 3Recruiting

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

Role: lead

NCT04905693Phase 3Enrolling By Invitation

Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease

Role: lead

NCT06878560Phase 1Recruiting

Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD

Role: lead

NCT06450041Phase 2Recruiting

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

Role: collaborator

NCT02573896Phase 1Active Not Recruiting

Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells

Role: collaborator

NCT03683186Phase 3Enrolling By Invitation

A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

Role: lead

NCT04708782Phase 3Completed

Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Role: lead

NCT05776225Recruiting

Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection

Role: lead

NCT03814317Phase 2Completed

Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension

Role: collaborator

NCT06388421Recruiting

DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Role: lead

NCT05421897Phase 1Active Not Recruiting

Rapid Administration Pilot for Infusing Dinutuximab

Role: collaborator

NCT01321073Not ApplicableActive Not Recruiting

DelIVery for Pulmonary Arterial Hypertension (PAH) & Continued Support Study

Role: collaborator

NCT03794583Phase 3Terminated

Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)

Role: lead

NCT05203510Phase 4Active Not Recruiting

A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension

Role: lead

NCT05564637Phase 2Completed

A Study of Treprostinil to Treat Interstitial Lung Disease Pulmonary Hypertension

Role: collaborator

NCT07261241Phase 2Not Yet Recruiting

NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab

Role: collaborator

NCT07224763Phase 1Recruiting

Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD

Role: lead